Why Amarin Investors Have Their Eyes on Nov. 14

So much for an accelerated approval timeline. Amarin (NASDAQ: AMRN) had once expected that the Food and Drug Administration would weigh in on a supplemental new drug application (sNDA) for Vascepa by the end of September. The drug earned priority review from regulators, who otherwise wouldn't have made a decision on the application until January 2020. But the accelerated timeline never materialized.